Surya P. Bhatt

Oct 8, 2024 | healio.com | Isabella Hornick |Kristen Dowd |Surya P. Bhatt

You've successfully added COPD to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Researchers measured health-related quality of life changes via the St. George’s Respiratory Questionnaire (SGRQ). Patients receiving dupilumab vs.

Sep 10, 2024 | healio.com | Isabella Hornick |Kristen Dowd |Surya P. Bhatt

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: At 52 weeks, patients receiving dupilumab vs. placebo had a lower annualized exacerbation rate and improved lung function. Dupilumab continued to be found well tolerated in this patient population.

Aug 23, 2024 | healio.com | Isabella Hornick |Kristen Dowd |Surya P. Bhatt

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Less than 5% of adults with COPD used pulmonary rehabilitation in 2019. One reason for low use of pulmonary rehabilitation is that clinicians and patients are unaware of the benefits it offers.

Jul 11, 2024 | atsjournals.org | Byron C. Jaeger |Use Policies |Surya P. Bhatt |Chaoqi Wu

Supplements PDF

Jun 17, 2024 | healio.com | Richard Gawel |Kristen Dowd |Surya P. Bhatt

Surya P. Bhatt, MD, MSPHAlthough derived from studies with a small number of subjects, the conclusion by experts that vaccines are effective while on treatment with dupilumab and that live vaccines are likely safe is an important clinical recommendation. With dupilumab being used in progressively lower age groups for a variety of indications that themselves are associated with high morbidity, no disseminated infections were reported post-vaccination.